---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-276845"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2026-06-22T13:17:24+00:00"
generated_at: "2026-06-22T13:18:11.859913+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health explores strategic alternatives; crofelemer NDA targeted for rare intestinal failure

## Summary
- Board initiated process to evaluate strategic alternatives including M&A, partnerships, and licensing to maximize shareholder value.
- Process aligns with planned completion of clinical work for NDA submission for crofelemer in rare intestinal failure diseases.
- Crofelemer reduced parenteral support by up to 37% in pediatric MVID/short bowel syndrome proof-of-concept trial.
- Third-party report estimates global nutritional support market for MVID at ~$1.1B in 2026, growing to ~$1.5B by 2033.
- CEO Lisa Conte to update on crofelemer program at Life Sciences Virtual Investor Forum on June 24, 2026.

## SEC filing metadata
- accession: 0001193125-26-276845
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2026-06-22T13:17:24+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000119312526276845/0001193125-26-276845-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000119312526276845/d27128d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-276845
- JSON: https://secwatch.observer/filing/0001193125-26-276845.json
- Plain text: https://secwatch.observer/filing/0001193125-26-276845.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.